PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Curr Opin Virol. Author manuscript; available in PMC Jun 1, 2013.
Published in final edited form as:
PMCID: PMC3514439
NIHMSID: NIHMS363275
Pathogenesis of acute respiratory illness caused by human parainfluenza viruses
Henrick Schomacker, Anne Schaap-Nutt, Peter L. Collins, and Alexander C. Schmidt*
Laboratory of Infectious Diseases, RNA Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services. Bethesda, MD, USA
*Corresponding author. Mailing address: LID, NIAID, NIH, 50 South Drive, Room 6515, MSC 8007, Bethesda, MD 20892. Phone: (301) 594-1650. Fax: (301) 480-1268. as337y/at/gmail.com
Human parainfluenza viruses (HPIVs) are a common cause of acute respiratory illness throughout life. Infants, children, and the immunocompromised are the most likely to develop severe disease. HPIV1 and HPIV2 are best known to cause croup while HPIV3 is a common cause of bronchiolitis and pneumonia. HPIVs replicate productively in respiratory epithelial cells and do not spread systemically unless the host is severely immunocompromised. Molecular studies have delineated how HPIVs evade and block cellular innate immune responses to permit efficient replication, local spread, and host-to-host transmission. Studies using ex vivo human airway epithelium have focused on virus tropism, cellular pathology and the epithelial inflammatory response, elucidating how events early in infection shape the adaptive immune response and disease outcome.
Human parainfluenza viruses (HPIVs) are a common cause of acute respiratory infections (ARIs) in infants and young children, with 80% of children testing seropositive for HPIV1, 2, and 3 by age five [1]. Re-infection with HPIV of the same serotype can occur throughout life but secondary infections are typically limited to the upper respiratory tract (URT). The majority of HPIV patients are treated in outpatient settings, yet HPIVs are a major cause of hospitalization for lower respiratory illness (LRI) in children under five years of age, second only to respiratory syncytial virus (RSV) [2-5]. In this age group, HPIVs are a more common cause of hospitalization for ARI or fever than influenza viruses, with a hospitalization rate of 1/1000/year, or approximately 23,000 hospitalizations per year in the United States alone [4-6]. Of the HPIVs, HPIV3 is the most frequent cause of hospitalization, followed by HPIV1 and 2 [5]. HPIV4 has been reported to be a much less frequent cause of clinically significant respiratory illness [7,8], although a more recent study found HPIV4 in 10% of all HPIV positive samples in a daycare setting [9]. Although significant progress has been made in the past decade toward the development of vaccines for HPIV1, 2, and 3, a licensed vaccine is not yet available and neither are specific antiviral drugs [3,4,10-14].
HPIV infection usually initiates at the epithelium of the URT following exposure by contact or inhalation. Infection frequently spreads to the paranasal sinuses, larynx and bronchi, and obstruction of the Eustachian tubes can lead to otitis media. Each of the HPIVs has been associated with a similar broad spectrum of respiratory tract disease including the common cold, croup, bronchitis, bronchiolitis, and pneumonia, but certain serotypes are more frequently associated with certain illnesses [3,4,10,11]. For example, HPIV1 and 2 are more frequently associated with laryngotracheobronchitis (croup), and HPIV3 is more likely than HPIV1 or 2 to spread to the smaller airways, causing bronchiolitis and pneumonia resembling that of RSV [2,15,16]. Apnea also is associated with HPIV LRI in the first few months of life [5]. Treatment for HPIV disease is largely supportive except in the case of croup, where effective symptomatic relief can be achieved with corticosteroids and nebulized epinephrine [17,18]. Infections are self-limiting. HPIV infection is rarely fatal in otherwise healthy individuals, but mortality can be high in severely immunosuppressed individuals such as hematopoietic stem cell transplant recipients [19,20]. It has been hypothesized that severe HPIV infections in young infants may sometimes have long-term effects on lung function and immunity, but this remains unclear.
The HPIVs are enveloped, non-segmented, negative-strand RNA viruses of subfamily Paramyxovirinae, family Paramyxoviridae [15,21]. HPIV1 and 3 belong to genus Respirovirus, while HPIV2 and 4 belong to genus Rubulavirus [21]. The genomes of HPIV1, 2, and 3 are similar in size (15.5-15.7 kb), whereas that of HPIV4 is somewhat larger (17.4 kb) [8]. They share the same order of 6 genes: 3’-N-P-M-F-HN-L, which are transcribed sequentially into separate mRNAs. There are two viral surface proteins: the hemagglutinin-neuraminidase (HN) protein, which mediates attachment to sialic acid residues on host cell membranes and cleavage of these residues during release, and the fusion (F) protein, which mediates the fusion of the viral envelope with the host cell membrane. These are the viral neutralization antigens and major protective antigens. The N protein coats the genomic RNA, forming a highly stable nucleocapsid. The phosphoprotein (P) and the large polymerase protein (L) are associated with the nucleocapsid, while the matrix protein (M) coats the inner surface of the envelope [15].
The P gene also encodes additional proteins that vary among viruses. These are called accessory proteins because they are not essential for virus replication in vitro. The most notable are the C and V proteins, which suppress host innate immune responses as described below. C proteins are expressed by a separate ORF that overlaps the P ORF and are encoded by HPIV1 and 3, but not by HPIV2 and 4, as is characteristic of their respective genera. The sequence of the C protein is not highly conserved and lacks evident motifs.
Expression of the V protein depends on a mechanism called “RNA editing”, whereby the polymerase stutters at a specific motif during transcription of the P gene to create mRNA species with frameshifts that link the upstream half of the P ORF to an internal V ORF encoding a protein domain with a characteristic zinc finger motif containing seven cysteine residues. Thus, V is a chimeric protein with an N-terminal domain encoded by the P ORF and a C-terminal domain encoded by the V ORF. All members of Paramyxovirinae express a V protein with the curious exceptions of HPIV1 and 3, which contain a relic V ORF that is not expressed in the case of HPIV1 [22] and is either not expressed or is expressed at a low level by HPIV3 [23,24]. The zinc finger motif of the V protein is conserved among all members of Paramyxovirinae and is necessary for suppression of both IFN induction and IFN signaling.
For cytoplasmic RNA viruses such as the HPIVs, the most potent stimulus for innate immunity is viral RNA synthesis, which can strongly activate host cytoplasmic sensors such as MDA5, RIG-I, and PKR. Downstream effects include: signal transduction that activates transcription factors IRF3 and NF-κB and induces IFN-β and pro-inflammatory cytokines; suppression of cellular translation by PKR; and IFN-induced signaling to induce an antiviral state [25-29]. These responses can strongly restrict HPIV replication but are inhibited in multiple ways by the viral V and C proteins [30,31].
The C ORF of HPIV1 encodes four C proteins called C’, C, Y1, and Y2 that originate from different translational start sites but share a common C-terminus [32,33]. HPIV1 C proteins have been shown to prevent IFN induction [34-36], IFN signaling [34], and apoptosis [35]. The HPIV1 C proteins do not appear to interact with or directly inhibit the signal transduction pathways leading to activation of IRF3 and NF-κB: instead, they modulate and reduce viral RNA synthesis to prevent the accumulation of dsRNA, thus avoiding activation of MDA5 and PKR [36]. With regard to IFN signaling, the HPIV1 C proteins have been shown to bind to STAT1 (but not STAT2), but not to interfere significantly with phosphorylation or stability of either STAT1 or 2. Rather, they sequester STAT1 in complexes that accumulate in the cytoplasm associated with late endosomes, thus preventing STAT1 translocation to the nucleus [37]. The mechanism by which the HPIV1 C proteins inhibit apoptosis remains unclear. Infection of respiratory epithelial cells with an HPIV1 mutant engineered to not express the C proteins resulted in changes in the expression of hundreds of cellular genes controlled by IRF3, NF-κB, and other factors, illustrating that C normally has a broad impact on the host response [38].
HPIV3 encodes a single C protein that is important for efficient replication in experimental animal models [23], but is less well characterized than that of HPIV1. The HPIV3 C protein down-regulates viral RNA synthesis [39], which may reduce the innate response. HPIV3 C inhibits IFN signaling by binding to STAT1 and inhibiting its phosphorylation [40,41]. Interestingly, the HPIV3 C protein enhances activation of the MAPK/ERK pathway, which promotes the cellular response to growth factors and is necessary for efficient viral replication [40].
The HPIV2 V protein has been shown to inhibit IFN induction [42], IFN signaling [43], and apoptosis [44]. The HPIV2 V protein inhibits IFN induction in two ways: by binding to and inhibiting the activation of MDA5 [45,46], and by serving as an alternative, competing substrate for cellular kinases in the signal transduction for IRF3 activation [47]. HPIV2 V protein also appears to reduce the production of viral RNA [48], reminiscent of the C proteins noted above. HPIV2 V protein inhibits IFN signaling by binding to and promoting the degradation of STAT2 [49,50]. Overall, inhibition of IFN induction appears to be more important for efficient HPIV2 replication in vivo than inhibition of IFN signaling: recombinant HPIV2 viruses carrying V protein point mutations allowing IFN induction are attenuated in non-human primates [51], while HPIV2 viruses carrying V protein point mutations allowing IFN signaling are not attenuated [44]. This difference may reflect the ability of secreted IFN to affect cells beyond those directly infected with virus, while virus-mediated inhibition of IFN signaling operates only in infected cells.
The ability of HPIV4 to interfere with host innate immunity is less well characterized. Surprisingly, HPIV4 does not appear to interfere with IFN signaling [52]. It is possible that this contributes to its reduced virulence. It seems likely that HPIV4 has the ability to inhibit IFN induction, although investigation of this has not been reported.
HPIVs replicate to high titer in the epithelial cells that line the respiratory tract [53-55]. In an in vitro model of well-differentiated mucociliary human airway epithelium (HAE) [56,57], HPIV1, 2, and 3 infected only the superficial ciliated cells on the apical (lumenal) face and did not spread to the underlying basal cells or goblet cells [53-55]. The release of progeny HPIV1, 2, and 3 occurred solely at the apical surface. This selective tropism is consistent with the absence of viremia in otherwise healthy individuals. This tropism also may limit exposure of viral antigen to antigen presenting cells, possibly leading to reduced immune responses that may allow re-infection. Low infectivity of HPIV3 for human dendritic cells may have a similar effect [58].
HPIV infection of non-polarized cell lines in vitro is characterized by syncytium formation leading to cytopathology. In contrast, HPIV infection of HAE cultures causes minimal gross cytopathology, with no evidence of cell-to-cell fusion, in contrast to the rapid tissue destruction caused by influenza A virus [53-55,59]. In explanation for the lack of syncytium formation, the HPIV3 F protein was found to be localized solely on the apical surface of these polarized cultures and thus did not contact neighboring cells. In post-mortem studies of human lung tissue, syncytium formation has been observed in the lungs of HPIV-infected individuals with severe immune deficiency or immunosuppression but is uncommon in immunocompetent patients [60-64]. HPIVs also strongly suppress apoptosis, which would reduce cytopathology.
Viremia and infection beyond the superficial respiratory epithelium are rare with HPIV infection. One likely factor is the directional budding of virions noted above. Another important factor is host immunity: systemic spread of HPIV has been detected only in severely immunocompromised patients [19,20,65].
Young age and lack of prior exposure to the infecting HPIV serotype are two major factors associated with HPIV LRI. Young infants are at greater risk in part because their smaller airways are more susceptible to obstruction, and their immune responses are reduced due to immunological immaturity and the presence of HPIV-specific maternal antibodies that suppress antibody responses (reviewed in [15,66]). Host genetic factors, particularly those affecting innate and inflammatory responses, likely also play a role, as has been investigated in greater detail for RSV [15,67].
It is generally thought that the respiratory pathology observed in vivo can be attributed to (i) high levels of virus replication and resulting direct virus-mediated effects, and (ii) the host response to infection. However, the relative contributions of these two factors are unclear and may be situational. While HPIV infection is not rapidly cytopathic in HAE cultures, infection appears to accelerate the normal mechanism of epithelial cell shedding and replacement [53]. The number of mucin-containing cells in HAE cultures increases during HPIV infection, consistent with the increased mucus production seen in HPIV-infected individuals. Also, HPIV infection inhibits ciliary motility in HAE cultures, an effect that in vivo would impede clearance of mucus and exfoliated cells from the airways. Airway inflammation and obstruction are certainly important components of HPIV pathogenesis. The histopathology of RSV bronchiolitis and pneumonia, which has been studied in more detail, also is characterized by obstruction of the small airways by inflammatory cell debris, edema, and external compression of the bronchioles from hyperplastic lymphoid follicles [68,69].
HPIV infection induces innate immune responses, serum and mucosal antibody responses, and CD8+ and CD4+ T-cell responses that restrict replication and clear HPIV infection. Neutralizing antibodies that target the HN and F glycoproteins are the most important determinants of long-term protection from HPIV disease [70-72]. Serum IgG antibodies provide the most durable protection against re-infection, but transport to the respiratory lumen is mostly non-specific and inefficient, and protection depends on high serum titers. Maternal IgG is thought to provide protection to infants for the first weeks or months of life. Studies in adults showed that detection of mucosal neutralizing antibody titers was a better correlate of protection than serum titers [70]. Mucosal IgA is transported efficiently through the epithelium to the airway lumen and can neutralize virus within infected epithelial cells, though IgA protection may be relatively short-lived compared with serum neutralizing antibodies. More than one infection is likely needed to maintain protective titers of mucosal IgA. The difficulty in maintaining protective levels of IgA and IgG in the respiratory lumen is an important factor in the ability of the HPIVs to re-infect (especially in the URT) throughout life. However, immunity from prior exposure typically limits re-infections to mild disease [73].
HPIV infection of the airway epithelium causes extensive changes in cellular gene expression and stimulates increased production of numerous cytokines and chemokines that either have antiviral functions themselves or attract and activate cells that mediate an immune response ([38] and Schaap-Nutt et al., unpublished data). Microarray analysis of epithelial cells infected with HPIV1 has indicated that the NF-κB, IRF3 and type 1 IFN pathways play a major role in regulating the cellular antiviral and inflammatory response to HPIV1 infection, and the HPIV1 C proteins normally suppress activation of these pathways [38]. Correlating with the microarray data, elevated nasal wash concentrations of inflammatory cytokines, including IL-8/CXCL8, MIP1α+1β/CCL3+4, RANTES/CCL5, and CXCL9, have been described in case series of children with HPIV disease [74,75]. Patients with primary HPIV infections also develop detectable IFN responses during acute infection [76]. CXCR3 ligands such as IP-10 and I-TAC, which attract activated Th1 cells to the infected epithelium, are the dominant chemokines known to be produced during HPIV infection and are secreted by the airway epithelium as well as by monocytes and neutrophils ([77-79] and Schaap-Nutt et al., unpublished data). High concentrations of IL-8 and IP-10, in particular, have been correlated with more severe HPIV disease [74,75]. It is unclear whether the association between the magnitude of inflammatory responses and disease severity reflects a specific pathogenic feature of these viruses, or the magnitude of virus replication resulting in increased immune responses, or both.
HPIV infections are common throughout life, and disease severity is greatest in the immunologically naïve and the immunocompromised. The magnitude of HPIV replication is a major factor determining severity of illness [80]. The viral C and V accessory proteins are key players in suppression of the innate immune response to HPIV infection, thus enabling efficient virus replication. The response of the airway epithelium to infection is crucial for initiating an inflammatory and innate immune response, but inflammatory cytokine production and subsequent cellular infiltration may also contribute to HPIV pathogenesis. A better understanding of HPIV pathogenesis will aid the design and evaluation of live-attenuated HPIV vaccines and therapeutic drugs.
Highlights
  • HPIVs evade the innate immune response and replicate efficiently in respiratory epithelium
  • Cellular pathology in ex vivo epithelium is limited
  • Previous homotypic HPIV infections protect against severe disease, not against infection
  • There are no licensed vaccines or specific antiviral drugs for the HPIVs
Acknowledgments
The authors are funded by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.
Footnotes
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
1*. Cooney MK, Fox JP, Hall CE. The Seattle Virus Watch. VI. Observations of infections with and illness due to parainfluenza, mumps and respiratory syncytial viruses and Mycoplasma pneumoniae. Am J Epidemiol. 1975;101:532–551. This article and related publications cover the results of the Seattle Virus Watch, which enrolled families between 1969 to 1974 and monitored infections caused by different viruses during childhood. [PubMed]
2. Welliver RC, Wong DT, Sun M, McCarthy N. Parainfluenza virus bronchiolitis. Epidemiology and pathogenesis. Am J Dis Child. 1986;140:34–40. [PubMed]
3. Reed G, Jewett PH, Thompson J, Tollefson S, Wright PF. Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children < 5 years old. J Infect Dis. 1997;175:807–813. [PubMed]
4. Counihan ME, Shay DK, Holman RC, Lowther SA, Anderson LJ. Human parainfluenza virus-associated hospitalizations among children less than five years of age in the United States. Pediatr Infect Dis J. 2001;20:646–653. [PubMed]
5**. Weinberg GA, Hall CB, Iwane MK, Poehling KA, Edwards KM, Griffin MR, Staat MA, Curns AT, Erdman DD, Szilagyi PG. Parainfluenza virus infection of young children: estimates of the population-based burden of hospitalization. J Pediatr. 2009;154:694–699. Between 2000 and 2004, the New Vaccine Surveillance Network enrolled 2798 children under 5 with febrile or acute respiratory illness and reported that 6.9% of the infections leading to hospitalization are caused by human parainfluenza viruses. [PubMed]
6. Forster J, Ihorst G, Rieger CH, Stephan V, Frank HD, Gurth H, Berner R, Rohwedder A, Werchau H, Schumacher M, et al. Prospective population-based study of viral lower respiratory tract infections in children under 3 years of age (the PRI.DE study) Eur J Pediatr. 2004;163:709–716. [PubMed]
7. Billaud G, Morfin F, Vabret A, Boucher A, Gillet Y, Crassard N, Galambrun C, Ferraris O, Legrand L, Aymard M, et al. Human parainfluenza virus type 4 infections: a report of 20 cases from 1998 to 2002. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2005;34:48–51. [PubMed]
8. Yea C, Cheung R, Collins C, Adachi D, Nishikawa J, Tellier R. The complete sequence of a human parainfluenzavirus 4 genome. Viruses. 2009;1:26–41. [PMC free article] [PubMed]
9. Fairchok MP, Martin ET, Kuypers J, Englund JA. A Prospective Study of Parainfluenza Virus Type 4 Infections in Children Attending Daycare. Pediatric Infect Dis J. 2011;30:714–716. [PubMed]
10. Marx A, Torok TJ, Holman RC, Clarke MJ, Anderson LJ. Pediatric hospitalizations for croup (laryngotracheobronchitis): biennial increases associated with human parainfluenza virus 1 epidemics. J Infect Dis. 1997;176:1423–1427. [PubMed]
11. Rihkanen H, Ronkko E, Nieminen T, Komsi KL, Raty R, Saxen H, Ziegler T, Roivainen M, Soderlund-Venermo M, Beng AL, et al. Respiratory viruses in laryngeal croup of young children. The Journal of pediatrics. 2008;152:661–665. [PubMed]
12. Schmidt AC, Schaap-Nutt A, Bartlett EJ, Schomacker H, Boonyaratanakornkit J, Karron RA, Collins PL. Progress in the development of human parainfluenza virus vaccines. Expert review of respiratory medicine. 2011;5:515–526. [PMC free article] [PubMed]
13**. Karron RA, Thumar B, Schappell E, Surman S, Murphy BR, Collins PL, Schmidt AC. Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children. Vaccine. 2011 This reference and reference 14 describe the results of clinical trials with live attenuated HPIV3 vaccine candidates in seronegative children. The safety and immunogenicity of three potential vaccines are discussed. [PMC free article] [PubMed]
14. Karron RA, Casey R, Thumar B, Surman S, Murphy BR, Collins PL, Schmidt AC. The cDNA-derived investigational human parainfluenza virus type 3 vaccine rcp45 is well tolerated, infectious, and immunogenic in infants and young children. The Pediatric infectious disease journal. 2011;30:e186–191. [PMC free article] [PubMed]
15. Karron RA, Collins PL. Chapter 42. Parainfluenza Viruses. In: Knipe DM, Howley PM, editors. Fields Virology. Fifth. Vol. 1 Lippincott Williams & Wilkins; 2007. pp. 1497–1526.
16. Parrott R, Vargosko A, Luckey A, et al. Clinical features of infection with hemadsorption viruses. N Engl J Med. 1959;260:731–738. [PubMed]
17. Russell KF, Liang Y, O’Gorman K, Johnson DW, Klassen TP. Glucocorticoids for croup. Cochrane database of systematic reviews. 2011 CD001955. [PubMed]
18. Bjornson C, Russell KF, Vandermeer B, Durec T, Klassen TP, Johnson DW. Nebulized epinephrine for croup in children. Cochrane database of systematic reviews. 2011 CD006619. [PubMed]
19. Campbell AP, Chien JW, Kuypers J, Englund JA, Wald A, Guthrie KA, Corey L, Boeckh M. Respiratory virus pneumonia after hematopoietic cell transplantation (HCT): associations between viral load in bronchoalveolar lavage samples, viral RNA detection in serum samples, and clinical outcomes of HCT. The Journal of infectious diseases. 2010;201:1404–1413. [PMC free article] [PubMed]
20. Srinivasan A, Wang C, Yang J, Shenep JL, Leung WH, Hayden RT. Symptomatic parainfluenza virus infections in children undergoing hematopoietic stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2011;17:1520–1527. [PubMed]
21. Henrickson KJ. Parainfluenza viruses. Clin Microbiol Rev. 2003;16:242–264. [PMC free article] [PubMed]
22. Rochat S, Komada H, Kolakofsky D. Loss of V protein expression in human parainfluenza virus type 1 is not a recent event. Virus Res. 1992;24:137–144. [PubMed]
23. Durbin AP, McAuliffe JM, Collins PL, Murphy BR. Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates. Virology. 1999;261:319–330. [PubMed]
24. Galinski MS, Troy RM, Banerjee AK. RNA editing in the phosphoprotein gene of the human parainfluenza virus type 3. Virology. 1992;186:543–550. [PubMed]
25. Goodbourn S, Didcock L, Randall RE. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J Gen Virol. 2000;81:2341–2364. [PubMed]
26. Levy DE, Garcia-Sastre A. The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. Cytokine Growth Factor Rev. 2001;12:143–156. [PubMed]
27. Katze MG, He Y, Gale M., Jr Viruses and interferon: a fight for supremacy. Nat Rev Immunol. 2002;2:675–687. [PubMed]
28. Takaoka A, Yanai H. Interferon signalling network in innate defence. Cellular microbiology. 2006;8:907–922. [PubMed]
29. Goodbourn S, Randall RE. The regulation of type I interferon production by paramyxoviruses. J Interferon Cytokine Res. 2009;29:539–547. [PMC free article] [PubMed]
30. Horvath CM. Weapons of STAT destruction. Interferon evasion by paramyxovirus V protein. Eur J Biochem. 2004;271:4621–4628. [PubMed]
31. Gotoh B, Komatsu T, Takeuchi K, Yokoo J. Paramyxovirus strategies for evading the interferon response. Rev Med Virol. 2002;12:337–357. [PubMed]
32. Curran J, Kolakofsky D. Scanning independent ribosomal initiation of the Sendai virus Y proteins in vitro and in vivo. Embo J. 1989;8:521–526. [PubMed]
33. Boeck R, Curran J, Matsuoka Y, Compans R, Kolakofsky D. The parainfluenza virus type 1 P/C gene uses a very efficient GUG codon to start its C’ protein. J Virol. 1992;66:1765–1768. [PMC free article] [PubMed]
34. Van Cleve W, Amaro-Carambot E, Surman SR, Bekisz J, Collins PL, Zoon KC, Murphy BR, Skiadopoulos MH, Bartlett EJ. Attenuating mutations in the P/C gene of human parainfluenza virus type 1 (HPIV1) vaccine candidates abrogate the inhibition of both induction and signaling of type I interferon (IFN) by wild-type HPIV1. Virology. 2006;352:61–73. [PubMed]
35. Bartlett EJ, Cruz AM, Esker J, Castano A, Schomacker H, Surman SR, Hennessey M, Boonyaratanakornkit J, Pickles RJ, Collins PL, et al. Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primates. J Virol. 2008;82:8965–8977. [PMC free article] [PubMed]
36. Boonyaratanakornkit J, Bartlett E, Schomacker H, Surman S, Akira S, Bae YS, Collins P, Murphy B, Schmidt A. The C proteins of human parainfluenza virus type 1 limit double-stranded RNA accumulation that would otherwise trigger activation of MDA5 and protein kinase R. Journal of Virology. 2011;85:1495–1506. [PMC free article] [PubMed]
37. Schomacker H, Hebner RM, Boonyaratanakornkit J, Surman S, Amaro-Carambot E, Collins PL, Schmidt AC. The C proteins of Human Parainfluenza Virus Type 1 block IFN signaling by binding and retaining Stat1 in perinuclear aggregates at the late endosome. PLoS ONE. In press. [PMC free article] [PubMed]
38*. Boonyaratanakornkit JB, Bartlett EJ, Amaro-Carambot E, Collins PL, Murphy BR, Schmidt AC. The C proteins of human parainfluenza virus type 1 (HPIV1) control the transcription of a broad array of cellular genes that would otherwise respond to HPIV1 infection. Journal of virology. 2009;83:1892–1910. This publication shows how gene expression patterns differ between a parainfluenza virus that is able to suppress IFN induction and signaling (WT HPIV1) and a mutant that does not express an IFN antagonist protein (P(C-) HPIV1) [PMC free article] [PubMed]
39. Malur AG, Hoffman MA, Banerjee AK. The human parainfluenza virus type 3 (HPIV 3) C protein inhibits viral transcription. Virus Res. 2004;99:199–204. [PubMed]
40. Caignard G, Komarova AV, Bourai M, Mourez T, Jacob Y, Jones LM, Rozenberg F, Vabret A, Freymuth F, Tangy F, et al. Differential regulation of type I interferon and epidermal growth factor pathways by a human Respirovirus virulence factor. PLoS pathogens. 2009;5:e1000587. [PMC free article] [PubMed]
41. Malur AG, Chattopadhyay S, Maitra RK, Banerjee AK. Inhibition of STAT 1 phosphorylation by human parainfluenza virus type 3 C protein. J Virol. 2005;79:7877–7882. [PMC free article] [PubMed]
42. Poole E, He B, Lamb RA, Randall RE, Goodbourn S. The V proteins of Simian virus 5 and other paramyxoviruses inhibit induction of interferon-beta. Virology. 2002;303:33–46. [PubMed]
43. Parisien JP, Lau JF, Rodriguez JJ, Sullivan BM, Moscona A, Parks GD, Lamb RA, Horvath CM. The V protein of human parainfluenza virus 2 antagonizes type I interferon responses by destabilizing signal transducer and activator of transcription 2. Virology. 2001;283:230–239. [PubMed]
44. Schaap-Nutt A, D’Angelo C, Scull MA, Amaro-Carambot E, Nishio M, Pickles RJ, Collins PL, Murphy BR, Schmidt AC. Human parainfluenza virus type 2 V protein inhibits interferon production and signaling and is required for replication in non-human primates. Virology. 2010;397:285–298. [PMC free article] [PubMed]
45. Andrejeva J, Childs KS, Young DF, Carlos TS, Stock N, Goodbourn S, Randall RE. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proc Natl Acad Sci U S A. 2004;101:17264–17269. [PubMed]
46. Childs K, Stock N, Ross C, Andrejeva J, Hilton L, Skinner M, Randall R, Goodbourn S. mda-5, but not RIG-I, is a common target for paramyxovirus V proteins. Virology. 2007;359:190–200. [PubMed]
47. Lu LL, Puri M, Horvath CM, Sen GC. Select paramyxoviral V proteins inhibit IRF3 activation by acting as alternative substrates for inhibitor of kappaB kinase epsilon (IKKe)/TBK1. J Biol Chem. 2008;283:14269–14276. [PubMed]
48. Nishio M, Ohtsuka J, Tsurudome M, Nosaka T, Kolakofsky D. Human parainfluenza virus type 2 V protein inhibits genome replication by binding to the L protein: possible role in promoting viral fitness. J Virol. 2008;82:6130–6138. [PMC free article] [PubMed]
49*. Andrejeva J, Young DF, Goodbourn S, Randall RE. Degradation of STAT1 and STAT2 by the V proteins of simian virus 5 and human parainfluenza virus type 2, respectively: consequences for virus replication in the presence of alpha/beta and gamma interferons. J Virol. 2002;76:2159–2167. Here, the authors showed time that HPIV2 V proteins promote the degradation of Stat2, in contrast to the SV5 V protein, which promotes the degradation of Stat1. [PMC free article] [PubMed]
50. Schaap-Nutt A, D’Angelo C, Amaro-Carambot E, Nolan SM, Davis S, Wise SM, Higgins C, Bradley K, Kim O, Mayor R, et al. Recombinant human parainfluenza virus type 2 with mutations in V that permit cellular interferon signaling are not attenuated in non-human primates. Virology. 2010;406:65–79. [PMC free article] [PubMed]
51. Schaap-Nutt A, Higgins C, Amaro-Carambot E, Nolan SM, D’Angelo C, Murphy BR, Collins PL, Schmidt AC. Identification of human parainfluenza virus type 2 (HPIV-2) V protein amino acid residues that reduce binding of V to MDA5 and attenuate HPIV-2 replication in nonhuman primates. Journal of virology. 2011;85:4007–4019. [PMC free article] [PubMed]
52. Nishio M, Tsurudome M, Ito M, Ito Y. Human parainfluenza virus type 4 is incapable of evading the interferon-induced antiviral effect. Journal of virology. 2005;79:14756–14768. [PMC free article] [PubMed]
53**. Zhang L, Bukreyev A, Thompson CI, Watson B, Peeples ME, Collins PL, Pickles RJ. Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium. J Virol. 2005;79:1113–1124. The first publication exploring HPIV tropism using the HAE model, establishing that HPIV3 only infects the superficial ciliated cells with minimal cytopathology. [PMC free article] [PubMed]
54. Schaap-Nutt A, Scull MA, Schmidt AC, Murphy BR, Pickles RJ. Growth restriction of an experimental live attenuated human parainfluenza virus type 2 vaccine in human ciliated airway epithelium in vitro parallels attenuation in African green monkeys. Vaccine. 2010;28:2788–2798. [PMC free article] [PubMed]
55. Bartlett EJ, Hennessey M, Skiadopoulos MH, Schmidt AC, Collins PL, Murphy BR, Pickles RJ. Role of interferon in the replication of human parainfluenza virus type 1 wild type and mutant viruses in human ciliated airway epithelium. J Virol. 2008;82:8059–8070. [PMC free article] [PubMed]
56. Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW, Boucher RC. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell. 1998;95:1005–1015. [PubMed]
57. Pickles RJ, McCarty D, Matsui H, Hart PJ, Randell SH, Boucher RC. Limited entry of adenovirus vectors into well-differentiated airway epithelium is responsible for inefficient gene transfer. J Virol. 1998;72:6014–6023. [PMC free article] [PubMed]
58. Le Nouen C, Munir S, Losq S, Winter CC, McCarty T, Stephany DA, Holmes KL, Bukreyev A, Rabin RL, Collins PL, et al. Infection and maturation of monocyte-derived human dendritic cells by human respiratory syncytial virus, human metapneumovirus, and human parainfluenza virus type 3. Virology. 2009;385:169–182. [PMC free article] [PubMed]
59. Palermo LM, Porotto M, Yokoyama CC, Palmer SG, Mungall BA, Greengard O, Niewiesk S, Moscona A. Human parainfluenza virus infection of the airway epithelium: viral hemagglutinin-neuraminidase regulates fusion protein activation and modulates infectivity. Journal of virology. 2009;83:6900–6908. [PMC free article] [PubMed]
60. Downham MA, Gardner PS, McQuillin J, Ferris JA. Role of respiratory viruses in childhood mortality. Br Med J. 1975;1:235–239. [PMC free article] [PubMed]
61. Delage G, Brochu P, Pelletier M, Jasmin G, Lapointe N. Giant-cell pneumonia caused by parainfluenza virus. J Pediatr. 1979;94:426–429. [PubMed]
62. Aherne W, Bird T, Court SD, Gardner PS, McQuillin J. Pathological changes in virus infections of the lower respiratory tract in children. J Clin Pathol. 1970;23:7–18. [PMC free article] [PubMed]
63. Jarvis WR, Middleton PJ, Gelfand EW. Parainfluenza pneumonia in severe combined immunodeficiency disease. J Pediatr. 1979;94:423–425. [PubMed]
64. Weintrub PS, Sullender WM, Lombard C, Link MP, Arvin A. Giant cell pneumonia caused by parainfluenza type 3 in a patient with acute myelomonocytic leukemia. Arch Pathol Lab Med. 1987;111:569–570. [PubMed]
65. Madden JF, Burchette JL, Jr, Hale LP. Pathology of parainfluenza virus infection in patients with congenital immunodeficiency syndromes. Human pathology. 2004;35:594–603. [PubMed]
66. Crowe JE, Jr, Williams JV. Immunology of viral respiratory tract infection in infancy. Paediatr Respir Rev. 2003;4:112–119. [PubMed]
67. Miyairi I, DeVincenzo JP. Human genetic factors and respiratory syncytial virus disease severity. Clinical microbiology reviews. 2008;21:686–703. [PMC free article] [PubMed]
68. do Carmo Debur M, Raboni SM, Flizikowski FB, Chong DC, Persicote AP, Nogueira MB, Rosele LV, de Almeida SM, de Noronha L. Immunohistochemical assessment of respiratory viruses in necropsy samples from lethal non-pandemic seasonal respiratory infections. Journal of clinical pathology. 2010;63:930–934. [PubMed]
69. Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol. 2007;20:108–119. [PubMed]
70*. Smith CB, Purcell RH, Bellanti JA, Chanock RM. Protective effect of antibody to parainfluenza type 1 virus. N Engl J Med. 1966;275:1145–1152. This article established that neutralizing mucosal antibodies are a good correlate of protection from HPIV infections and are more effective than neutralizing serum antibodies. [PubMed]
71. Spriggs MK, Murphy BR, Prince GA, Olmsted RA, Collins PL. Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity. J Virol. 1987;61:3416–3423. [PMC free article] [PubMed]
72. Murphy BR, Prince GA, Collins PL, Van Wyke Coelingh K, Olmsted RA, Spriggs MK, Parrott RH, Kim HW, Brandt CD, Chanock RM. Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses. Virus Res. 1988;11:1–15. [PubMed]
73. Glezen WP, Frank AL, Taber LH, Kasel JA. Parainfluenza virus type 3: seasonality and risk of infection and reinfection in young children. J Infect Dis. 1984;150:851–857. [PubMed]
74. El Feghaly RE, McGann L, Bonville CA, Branigan PJ, Suryadevera M, Rosenberg HF, Domachowske JB. Local production of inflammatory mediators during childhood parainfluenza virus infection. The Pediatric infectious disease journal. 2010;29:e26–31. [PMC free article] [PubMed]
75. Gern JE, Martin MS, Anklam KA, Shen K, Roberg KA, Carlson-Dakes KT, Adler K, Gilbertson-White S, Hamilton R, Shult PA, et al. Relationships among specific viral pathogens, virus-induced interleukin-8, and respiratory symptoms in infancy. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2002;13:386–393. [PubMed]
76. Hall CB, Douglas RG, Jr, Simons RL, Geiman JM. Interferon production in children with respiratory syncytial, influenza, and parainfluenza virus infections. J Pediatr. 1978;93:28–32. [PubMed]
77. Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, McCormick M, Haldar K, Kebadze T, Duvoix A, et al. Acute Exacerbations of COPD: Identification of Biological Clusters and Their Biomarkers. American journal of respiratory and critical care medicine. 2011 [PubMed]
78. Sumino KC, Walter MJ, Mikols CL, Thompson SA, Gaudreault-Keener M, Arens MQ, Agapov E, Hormozdi D, Gaynor AM, Holtzman MJ, et al. Detection of respiratory viruses and the associated chemokine responses in serious acute respiratory illness. Thorax. 2010;65:639–644. [PMC free article] [PubMed]
79. McNamara PS, Flanagan BF, Hart CA, Smyth RL. Production of chemokines in the lungs of infants with severe respiratory syncytial virus bronchiolitis. The Journal of infectious diseases. 2005;191:1225–1232. [PubMed]
80. Utokaparch S, Marchant D, Gosselink JV, McDonough JE, Thomas EE, Hogg JC, Hegele RG. The relationship between respiratory viral loads and diagnosis in children presenting to a pediatric hospital emergency department. The Pediatric infectious disease journal. 2011;30:e18–23. [PubMed]